COVID-19 may be the latest challenge to primary care physicians, but it’s just one of many threatening the profession, including the increased focus on specialty drug markets—if PCPs are left out of the equation.
Stanton R. Mehr
Advertisement
Freelance writer who covers pharmaceutical care and clinical topics, health policy, and drug coverage issues
Articles by Stanton R. Mehr
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Novo Nordisk Announces Major Shake Ups to Board
4
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
5
